Traws Share Price
NASDAQ: TRAW | Micro Cap | HealthcareTraws Stock Performance
Traws Share Price Chart
Traws Quarterly Profit & Loss
All figures in USD
Traws Annual Profit & Loss
All figures in USD
Traws Balance Sheet
All figures in USD Million
Traws Cash Flow
All figures in USD Million
Corporate Actions
About Traws
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Traws Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $0.30 | $0.25 | -15.17% |
Oct 2026 | $0.56 | $0.29 | -51.67% |
Sep 2026 | $0.56 | $0.60 | +13.21% |
Aug 2026 | $0.45 | $0.53 | +18.04% |
Jul 2026 | $0.82 | $0.45 | -45.38% |
Jun 2026 | $1.47 | $0.82 | -43.51% |
May 2026 | $1.45 | $1.46 | +2.46% |
Apr 2026 | $1.73 | $1.42 | -20.67% |
Mar 2026 | $1.51 | $1.79 | +9.15% |
Feb 2026 | $2.04 | $1.64 | -23.72% |
Jan 2026 | $1.17 | $2.15 | +95.45% |
Dec 2025 | $2.73 | $1.10 | -59.26% |